Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Finally, possible correlations among C-RAF, H-RAS, MAPK1, MAPK2, pERK and iERK vs. other COVID-19-related biomarkers (VEGF, HIF, TNFα, vitamin D, hepcidin, ICAM-1, VCAM, MMP9, IL-6) were evaluated: C-RAF with age (p = 0.047, S = 0.309) and plasma VEGF (p = 0.026, S = 0.729); MAPK1 and HIF (p = 0.050, S = 0.812); iERK and HIF (p = 0.008, S = 0.928); pERK with TNFα (p = 0.012, S = −0.365) and vitamin D levels at baseline (p = 0.024, S = −0.643).

Source: 3.5. Correlations. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Negative participants were considered people who were negative for SARS-CoV-2 detection and without diagnosed pathologies, aged within 18 to 70 years.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

COVID-19: A Possible Contribution of the MAPK Pathway

Study design awaiting verification · Biomedicines · 2023

Original publication title

COVID-19: A Possible Contribution of the MAPK Pathway

Jessica Cusato; Alessandra Manca; Alice Palermiti; Jacopo Mula; Martina Costanzo; Miriam Antonucci; Mattia Trunfio; Silvia Corcione; Francesco Chiara; Elisa Delia De Vivo; Alice Ianniello; Micol Ferrara; Giovanni Di Perri; Francesco Giuseppe De Rosa; Antonio D’Avolio; Andrea Calcagno

© 2023 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background: COVID-19 is characterized by an uncontrolled inflammatory response with high pro-inflammatory cytokine production through the activation of intracellular pathways, such as mitogen-activated protein kinase (MAPK). Viruses are able to exploit the MAPK pathway to their advantage; this pathway relevance to severe COVID-19 is poorly described. The aim of this study was to quantify biomarkers involved in the MAPK pathway and to clarify its possible role in affecting some COVID-19-related clinical features. Methods: H-RAS, C-RAF, MAPK1, MAPK2, and ERK were quantified through ELISA, and genetic polymorphisms were evaluated through real-time PCR.

Results: We prospectively recruited 201 individuals (158 positive and 43 negative for SARS-CoV-2): 35 were male, and their median age was 65 years. MAPK-related biomarker levels were increased in SARS-CoV-2-positive participants (n = 89) compared to negative ones (n = 29). Dyspnea was reported by 48%; this symptom was associated with PBMC C-RAF levels in positive participants (p = 0.022) and type of ventilation (p = 0.031). The highest degree of ventilation was used by 8% for invasive ventilation and 41% for continuous positive airway pressure (CPAP).

Conclusions: This is the first study that showed a possible contribution of MAPK-related biomarkers in affecting COVID-19 clinical features, and this may be relevant for identifying COVID-19 positive participants at risk of serious complications.

Authors’ abstract

Background: COVID-19 is characterized by an uncontrolled inflammatory response with high pro-inflammatory cytokine production through the activation of intracellular pathways, such as mitogen-activated protein kinase (MAPK). Viruses are able to exploit the MAPK pathway to their advantage; this pathway relevance to severe COVID-19 is poorly described. The aim of this study was to quantify biomarkers involved in the MAPK pathway and to clarify its possible role in affecting some COVID-19-related clinical features. Methods: H-RAS, C-RAF, MAPK1, MAPK2, and ERK were quantified through ELISA, and genetic polymorphisms were evaluated through real-time PCR.

Results: We prospectively recruited 201 individuals (158 positive and 43 negative for SARS-CoV-2): 35 were male, and their median age was 65 years. MAPK-related biomarker levels were increased in SARS-CoV-2-positive participants (n = 89) compared to negative ones (n = 29). Dyspnea was reported by 48%; this symptom was associated with PBMC C-RAF levels in positive participants (p = 0.022) and type of ventilation (p = 0.031). The highest degree of ventilation was used by 8% for invasive ventilation and 41% for continuous positive airway pressure (CPAP).

Conclusions: This is the first study that showed a possible contribution of MAPK-related biomarkers in affecting COVID-19 clinical features, and this may be relevant for identifying COVID-19 positive participants at risk of serious complications.

Publication and source details

Original title: COVID-19: A Possible Contribution of the MAPK Pathway

Jessica Cusato; Alessandra Manca; Alice Palermiti; Jacopo Mula; Martina Costanzo; Miriam Antonucci; Mattia Trunfio; Silvia Corcione; Francesco Chiara; Elisa Delia De Vivo; Alice Ianniello; Micol Ferrara; Giovanni Di Perri; Francesco Giuseppe De Rosa; Antonio D’Avolio; Andrea Calcagno

Biomedicines · 2023

* Correspondence: alice.palermiti@unito.it (A.P.); jacopo.mula@unito.it (J.M.); Tel.: +39-011-4393867 (A.P. & J.M.); Fax: +39-011-4393996 (A.P. & J.M.)
†

These authors equally contributed to this work as co-first authors.

‡

These authors equally contributed to this work as co-last authors.

© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).University of TurinCUSJ_RILO_20_01CALA_RILO_20_01This research received local fundings (ex60%, funded by the University of Turin, codes CUSJ_RILO_20_01 and CALA_RILO_20_01).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T19:18:13.989997+00:00

DOI: 10.3390/biomedicines11051459 · PMC10216575